September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
June 2024 in “Georgetown medical review” Finasteride treats hair loss but may cause low libido, erectile issues, and depression.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
August 2023 in “Malaysian Journal of Medicine and Health Sciences/Malaysian journal of medicine and health sciences” Pueraria mirifica extract may help treat benign prostatic hyperplasia.
January 2022 in “International Journal of Science and Research (IJSR)” Certain medications can cause hair loss, which varies in severity and can be treated with specific drugs.
April 2019 in “Advances in Cosmetic Surgery” The document concludes that ongoing medical therapy is crucial for preventing hair loss, and surgical options can restore hair, with future treatments for hair loss being promising.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
November 2017 in “JAMA internal medicine” Women also use 5α-reductase inhibitors, and their effects differ from men.
January 2017 in “Elsevier eBooks” Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.
The conclusion is that endocrinology significantly impacts medicine with various common medications used for treatment.
Most American men experience hair loss by age 50, with limited effective treatments available and new options not expected soon.
September 2003 in “Clinics in Family Practice” Different hair diseases affect people during childbearing years, with treatments ranging from medication to psychological support.
January 2020 in “Archives of urology” Finasteride, a drug used for certain conditions, can cause serious side effects like sexual dysfunction, suicidal thoughts, and increased diabetes risk, and there's a need for more awareness and research about these effects.
October 2015 in “Elsevier eBooks” Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
November 2009 in “Cambridge University Press eBooks” Minoxidil and finasteride combined can effectively treat hair loss.
A rigid compound with a common structural motif was successfully synthesized.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
January 2025 in “Dermatology Review” Artefactual skin disorder involves self-inflicted skin lesions linked to mental health issues, needing combined medical and psychological treatment.
December 2023 in “International Journal of Research in Ayurveda and Pharmacy” Ayurvedic remedies may boost immunity and balance in cancer treatment but need more research.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
26 citations
,
December 2023 in “Prostate International” Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
These medications for BPH have known risks and may have new side effects.
These medications for BPH have known risks and may have new side effects.
July 2023 in “AYUSHDHARA” Aging is a natural process causing physical and mental decline.
December 2024 in “Journal of Applied Toxicology” High doses of dihydroartemisinin caused reversible liver toxicity in rats, with females more affected than males.
December 2024 in “Indian Dermatology Online Journal” Gemstones are used to help describe and remember skin conditions.
January 2025 in “INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS” January 2026 in “Zenodo (CERN European Organization for Nuclear Research)”